Does Aetna Cover Semaglutide (Wegovy)?

How Aetna Decides Whether to Cover Wegovy

Aetna does not have a single national formulary for all members. Coverage for Wegovy is determined by the type of plan you hold and the benefit design your employer or plan sponsor chose when they purchased the policy.

Commercial Fully-Insured Plans

On fully-insured commercial plans, Aetna follows its own clinical policy bulletin for anti-obesity pharmacotherapy. As of mid-2025, Aetna's published Clinical Policy Bulletin 0545 (Obesity Management) lists semaglutide 2.4 mg (Wegovy) as a covered benefit when prior authorization criteria are met. Those criteria typically include:

• A documented BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher plus at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea).
• A record of at least 6 months of supervised diet and exercise counseling with documented inadequate response.
• Absence of contraindications, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (per the FDA label for Wegovy) [1].

These are Aetna's internal thresholds. Your plan's actual criteria may be stricter or slightly more permissive depending on how the benefit was structured.

Self-Funded Employer Plans

Self-funded (ERISA) plans are designed by the employer, not Aetna. Aetna serves only as a third-party administrator in these cases. This means your employer bears the drug cost directly and can choose to exclude anti-obesity medications entirely, cap the covered duration, or add an additional BMI or comorbidity requirement. A 2023 analysis by the Kaiser Family Foundation found that only about 25% of large employers had added GLP-1 receptor agonists for weight loss to their covered benefit [2]. If your employer has excluded these drugs, Aetna cannot override that decision regardless of your medical need.

Medicare and Medicaid

Medicare Part D plans are prohibited by statute from covering drugs approved solely for weight loss or weight management. Because Wegovy's original FDA approval in June 2021 was for chronic weight management, most Medicare Part D plans exclude it [3]. The SELECT cardiovascular outcomes trial (N=17,604), published in the New England Journal of Medicine in 2023, demonstrated that semaglutide 2.4 mg reduced the rate of major adverse cardiovascular events by 20% versus placebo in patients with established cardiovascular disease and overweight or obesity (HR 0.80, 95% CI 0.72 to 0.90, P<0.001) [4]. Following FDA approval of the cardiovascular risk reduction indication in March 2024, CMS issued guidance allowing Part D plans to cover Wegovy specifically for that indication. Whether your Medicare Part D plan has actually added this coverage depends on the specific plan.

Medicaid is run at the state level. Most state Medicaid programs continue to exclude anti-obesity medications. A small number of states, including New York, have begun covering GLP-1 drugs for obesity through the Medicaid formulary, but this remains the exception rather than the rule [5].

Prior Authorization Requirements for Wegovy on Aetna Plans

Prior authorization is the single biggest access hurdle. Aetna requires it on essentially every plan that lists Wegovy as a covered drug.

What Your Prescriber Must Submit

The prior authorization packet typically needs to document:

1. Current height, weight, and calculated BMI.
2. The specific weight-related comorbidity if BMI is between 27 and 29.9 kg/m².
3. A treatment history showing at least 6 months of dietary counseling or a structured behavioral weight management program, with progress notes.
4. Any prior anti-obesity medications tried and the outcome (this is the step therapy requirement on many plans).
5. A statement ruling out contraindications (thyroid cancer history, MEN2, pregnancy).

The FDA label for Wegovy specifically states it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma [1]. Aetna's clinical reviewers check for this contraindication explicitly.

Step Therapy

Step therapy, sometimes called "fail-first" protocol, requires that a patient try at least one older, lower-cost medication before Wegovy will be approved. On plans with step therapy, the usual required agents are orlistat 120 mg three times daily (Xenical/Alli) or phentermine-topiramate extended-release (Qsymia). A 12-week trial with documented inadequate weight loss (typically defined as less than 5% body weight reduction) usually satisfies the step therapy requirement. Some plans specifically require only dietary and exercise counseling as the step, without a mandatory prior drug trial.

Processing Time

Standard prior authorization requests are processed within 3 business days under most state prompt-pay and utilization review laws. Urgent requests, for example in a patient with obesity-related heart failure exacerbation, must be processed within 72 hours. If Aetna does not respond within these windows, you can treat the non-response as a denial for appeal purposes.

What Aetna Covers Under the Cardiovascular Indication

The SELECT trial results changed the coverage conversation significantly. The trial enrolled 17,604 adults aged 45 years or older with a BMI of 27 kg/m² or higher and established cardiovascular disease but without diabetes. After a median follow-up of 39.8 months, semaglutide 2.4 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 20% compared with placebo [4].

Following FDA approval of this cardiovascular risk reduction indication in March 2024, Aetna updated its clinical policy language to recognize the indication. Medicare Part D plans can now reimburse Wegovy for this population. If you are a Medicare beneficiary with established cardiovascular disease and a BMI of 27 kg/m² or higher, your prescriber should specify the cardiovascular risk reduction indication on the prescription and the prior authorization form. This is a clinically and administratively distinct pathway from the obesity-only pathway.

The HealthRX clinical team has put together a decision framework for patients trying to determine which Aetna coverage pathway applies to them:

Step 1. Confirm your plan type (fully-insured commercial, self-funded, Medicare Part D, or Medicaid). This determines which rules govern your benefits.

Step 2. Check whether your BMI meets the threshold (30 kg/m² or higher for the obesity pathway, or 27 kg/m² or higher with a qualifying comorbidity).

Step 3. If you have established cardiovascular disease and are on Medicare or a commercial plan, ask your prescriber to specify the cardiovascular risk reduction indication on the PA form.

Step 4. Assemble documentation of prior diet/exercise counseling and any prior anti-obesity drug trials before submitting the PA request.

Step 5. If denied, file an internal appeal within 60 days and request an expedited external review if you have urgent clinical need.

What Wegovy Costs With and Without Aetna Coverage

List Price and Net Cost

The wholesale acquisition cost (WAC) for Wegovy is approximately $1,349 for a 28-day supply as of mid-2025. Most patients with commercial insurance who receive coverage pay a negotiated net price substantially below that, though their out-of-pocket cost still depends on their deductible and copay tier. Wegovy is typically placed on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) on Aetna formularies, which translates to copays ranging from roughly $60 to $200 per month after the deductible is met on plans that cover it.

Novo Nordisk Savings Programs

Novo Nordisk offers a Wegovy WeightLoss Card for commercially insured patients. Eligible patients with commercial insurance pay as little as $25 per 28-day supply for up to 24 months [6]. The savings card cannot be used for government-insured patients (Medicare, Medicaid, TRICARE). Patients without any insurance coverage may apply for the NovoCare Patient Assistance Program, which provides Wegovy at no cost to qualifying low-income individuals.

Compounded Semaglutide

During the 2022 to early 2025 FDA shortage period, many patients used compounded semaglutide from 503A and 503B pharmacies as a lower-cost alternative. The FDA removed semaglutide from the drug shortage list in February 2025, after which 503B outsourcing facilities were given a 90-day wind-down period and 503A pharmacies were directed to stop compounding immediately for most patients [7]. As of mid-2025, commercially available Wegovy has returned to adequate supply, and Aetna does not cover compounded semaglutide because it is not an FDA-approved product.

How to Appeal an Aetna Denial for Wegovy

Denials happen. A denial is not final. The Affordable Care Act requires insurers to provide a clear denial notice with the specific reason, and it gives you the right to both an internal appeal and an independent external review.

Internal Appeal

File an internal appeal within 60 days of the denial notice. Your prescriber should submit a letter of medical necessity that includes:

• Your current weight, BMI, and the comorbidities present.
• Published clinical evidence supporting Wegovy for your specific indication. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [8]. The STEP-5 trial (N=304) extended follow-up to 104 weeks and showed 15.2% mean weight loss maintained at 2 years [9].
• The AACE/ACE Clinical Practice Guidelines for Comprehensive Medical Care in Diabetes, which the American Association of Clinical Endocrinology updated in 2022, state that GLP-1 receptor agonist therapy should be considered as first-line pharmacotherapy for patients with obesity and type 2 diabetes [10].

External Review

If the internal appeal fails, request an independent external review from a state-certified independent review organization (IRO). Under the ACA, the IRO's decision is binding on the insurer. Studies of external review outcomes across all insurer types show that patients win roughly 40% to 50% of external reviews for specialty drugs [11].

State Insurance Commissioner

If Aetna violates prompt-pay or utilization review laws during the appeal process, file a complaint with your state insurance commissioner. Most states have online portals for this. Fully-insured plans are subject to state insurance law; self-funded ERISA plans are not, and disputes over self-funded benefits go through the Department of Labor.

Aetna's Coverage Compared to Other Major Insurers

Aetna's Wegovy coverage policies are broadly in line with UnitedHealthcare and Cigna, all of which require prior authorization and BMI-based criteria. Blue Cross Blue Shield plans vary by region. Express Scripts and CVS Caremark (which manages Aetna's pharmacy benefit on many plans) have each negotiated rebates with Novo Nordisk that influence formulary placement and tier assignment.

A notable exception is the federal government. The Treat and Reduce Obesity Act, if passed, would require Medicare Part D to cover FDA-approved anti-obesity medications broadly, not just under the cardiovascular indication. As of mid-2025, that legislation has not been enacted.

Employer-sponsored plans for federal civilian workers (FEHB) began covering Wegovy and other GLP-1 drugs for obesity starting in 2024 for many plan options. If you are a federal employee or retiree, check your specific FEHB plan brochure because coverage varies by carrier within the FEHB system.

Special Populations and Coverage Nuances

Patients With Type 2 Diabetes

Ozempic (semaglutide 0.5 mg, 1 mg, and 2 mg weekly) is FDA-approved for type 2 diabetes and is covered more broadly across Aetna plans than Wegovy because diabetes is a mainstream indication. If you have both obesity and type 2 diabetes, your prescriber may find it administratively easier to prescribe Ozempic under the diabetes indication. The clinical caveat is that Ozempic doses below 2 mg produce somewhat less weight loss than Wegovy 2.4 mg. The SUSTAIN-6 trial (N=3,297) demonstrated cardiovascular risk reduction with Ozempic in the diabetes setting, providing an additional clinical rationale [12].

Adolescents

The FDA approved Wegovy for chronic weight management in adolescents aged 12 and older in December 2022, based on the STEP TEENS trial (N=201), which showed 16.1% mean BMI reduction at 68 weeks versus 0.6% with placebo [13]. Aetna's coverage criteria for adolescents typically mirror the adult criteria with BMI expressed as BMI-for-age percentile (95th percentile or above, or 85th to 94th percentile with a comorbidity). Parental consent documentation is generally required in the prior authorization packet for patients under 18.

Pregnancy

Wegovy is contraindicated in pregnancy per its FDA label. Aetna's prior authorization forms ask about current pregnancy status and require a negative pregnancy test in women of childbearing potential on some plans. Prescriptions will not be approved or filled for pregnant patients [1].

Practical Steps Before Calling Aetna

Before you call Aetna's member services line (the number is on the back of your insurance card), gather the following:

1. Your Aetna member ID and group number.
2. The NDC (National Drug Code) for Wegovy: 00169-4230-12 for the 2.4 mg dose maintenance pen, though your pharmacy can confirm the current NDC.
3. Your prescriber's NPI number, fax number, and office contact for the prior authorization team.
4. A copy of your most recent weight and vital signs from a clinical visit dated within the past 90 days.

Ask the Aetna representative specifically: "Is Wegovy covered on my plan, what tier is it on, and what are the prior authorization criteria for my specific plan?" Then ask for the criteria in writing, either by mail or through your Aetna member portal. Written confirmation protects you if there is a discrepancy later.

The STEP-1 trial enrolled 1,961 adults with a BMI of 30 kg/m² or higher (or 27 kg/m² or higher with at least one weight-related comorbidity) and produced a mean weight loss of 14.9% at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo [8]. Presenting that evidence to your prescriber before the prior authorization submission strengthens the letter of medical necessity and may reduce the likelihood of an initial denial.